Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies

J Pharm Biomed Anal. 2014 Sep:98:307-10. doi: 10.1016/j.jpba.2014.05.016. Epub 2014 May 22.

Abstract

A sensitive and selective liquid chromatographic method using mass spectrometric detection was developed for the determination of diethylcarbamazine (DEC) in human plasma. DEC and its stable isotope internal standard d3-DEC were extracted from 0.25mL of human plasma using solid phase extraction. Chromatography was performed using a Phenomenex Synergi 4μ Fusion-RP column (2mm×250mm) with gradient elution. The retention time was approximately 4.8min. The assay was linear from 4 to 2200ng/mL. Analysis of quality control samples at 12, 300, and 1700ng/mL (N=15) had interday coefficients of variation of 8.4%, 5.4%, and 6.2%, respectively (N=15). Interday bias results were -2.2%, 6.0%, and 0.8%, respectively. Recovery of DEC from plasma ranged from 84.2% to 90.1%. The method was successfully applied to clinical samples from patients with lymphatic filariasis from a drug-drug interaction study between DEC and albendazole and/or ivermectin.

Keywords: Antifilarial; Diethylcarbamazine; Liquid chromatography–mass spectrometry; Plasma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albendazole / blood
  • Albendazole / chemistry
  • Chromatography, Liquid / methods
  • Diethylcarbamazine / blood*
  • Diethylcarbamazine / chemistry*
  • Elephantiasis, Filarial / blood
  • Humans
  • Ivermectin / blood
  • Ivermectin / chemistry
  • Mass Spectrometry / methods
  • Plasma / chemistry*
  • Solid Phase Extraction / methods

Substances

  • Ivermectin
  • Albendazole
  • Diethylcarbamazine